格拉司琼动脉注射预防动脉化疗恶心呕吐的临床研究

目的探讨格拉司琼联合地塞米松动脉注射预防肿瘤动脉导管介入栓塞化疗恶心呕吐的疗效及不良反应。方法回顾性分析221例肝癌动脉介入栓塞化疗病例。观察组133例：动脉插管成功后注入格拉司琼3mg及地塞米松10mg；对照组88例：动脉注入胃复安30mg及地塞米松10mg。分别观察第1、2、3天内的恶心、呕吐发生率，治疗前后进行KPS评分。结果观察组第1天、第2天、第3天有效率分别为：86．5％、85．7％、95．5％；对照组分别为：55．7％、42．1％、84．1％．两组KPS评分下降率分别为：23．3％、47，7％。观察组优于对照组，相差均有显著性。观察组不良反应以便秘为主，无锥体外系反应，对照组锥体外系反应发生率14．8％。结论格拉司琼联合地塞米松动脉注射预防恶性肿瘤动脉介入栓塞化疗的恶心呕吐有效率高，不良反应轻。

A Clinical Study of Granisetron Artery Infusion in the Prevention of Nausea and Vomiting Induced by Arterial Chemotherapy

Objective To evaluate the curative effect and safety of Granisetron plus Dexamethasong artery infusion in the prevention of nausea and vomiting induced by conditioning for transcatbeter arterial chemoembolization on tumor. Methods Retrospective study of the 221 cases with hepatic carcinoma, they were treated by transcatheter arterial chemoembolization. The 133 cases in the treatment group were cured by Granisetron plus Dexamethasong artery infusion after put the tube into the artery successfully. And 88 cases in the contrasting group were infused by Metoclopramide plus Dexamethasong. We observed the occurrence rate of nausea and vomiting in the first day, the second day and the third day respectively, We carried on the Karhofsky performance status score during the treatment. Results In the first day,. the second day and the third day, response rates in the treatment group were 86.5 %, 85.7 %, 95.5 %, respectively. And the response rates of contrasting group were 55.7 %, 42.1%, 84,1%, respectively, The decline rates of Karnofsky performance status score were 23.3% and 47,7%. The response rates of treatment group were better. They all were statistically significantly different in the two groups. The main bad reaction in the treatment group was constipating. No extrapyramidal syndrome. And the occurrence rate of extrapyramidal syndrome in the contrasting group was observed in 14.8 %. Conclusions The efficacy rate of Granisetron plus Dexamethasong artery infusion in the prevention of nausea and vomiting induced by conditioning for transcatheter arterial chemoembolization on malignant tumor was higher. The bad reaction was lighter.